Drug development is an arduous and expensive exercise. We seek to produce innovative compounds efficiently and effectively.

SEC Filings

Filing	Description	Date Filed	Size
8-K	current report	Feb 2, 2012	158.7 KB
8-K	current report	Jan 31, 2012	22.5 KB
4	wysenski, nancy	Jan 23, 2012	31.7 KB
4	smith, ian f	Jan 23, 2012	31.9 KB
4	sachdev, amit	Jan 23, 2012	32.1 KB
4	kelly, lisa	Jan 23, 2012	32.1 KB
CT ORDER	confidential treatment order	Jan 5, 2012	6.1 KB
4	leiden, jeffrey m	Dec 16, 2011	32.9 KB
8-K	current report	Dec 16, 2011	29.3 KB
4	wysenski, nancy	Dec 13, 2011	31.7 KB
4	boger, joshua s	Dec 7, 2011	25.0 KB
4	boger, joshua s	Dec 2, 2011	26.3 KB
4	boger, joshua s	Nov 28, 2011	26.2 KB
4	boger, joshua s	Nov 17, 2011	26.2 KB
4	wysenski, nancy	Nov 16, 2011	31.8 KB
4	smith, ian f	Nov 16, 2011	32.0 KB
4	silva, paul m	Nov 16, 2011	31.2 KB
4	boger, joshua s	Nov 14, 2011	26.7 KB
10-Q	quarterly report	Nov 3, 2011	583.4 KB
4	boger, joshua s	Nov 3, 2011	26.7 KB
Showing 1-20 of 1300 Page: 1 2 3 ... 65  Next 20